| Literature DB >> 31750991 |
Mariane Le Fur1, Nicholas J Rotile1, Carlos Correcher2, Veronica Clavijo Jordan1, Alana W Ross1, Ciprian Catana1, Peter Caravan1.
Abstract
Gadolinium-based contrast agents (GBCAs) are used to provide diagnostic information in clinical magnetic resonance (MR) examinations. Gadolinium (Gd) has been detected in the brain, bone and skin of patients, months and years following GBCA administration, raising concerns about long term toxicity. Despite increased scrutiny, the concentration, chemical form and fate of the retained gadolinium species remain unknown. Importantly, the whole body biodistribution and organ clearance of GBCAs is poorly understood in humans. Gadolinium lacks suitable isotopes for nuclear imaging. We demonstrate that the yttrium-86 isotope can be used as a gadolinium surrogate. We show that Gd and their analogous Y complexes have similar properties both in solution and in vivo, and that yttrium-86 PET can be used to track the biodistribution of GBCAs over a two-day period.Entities:
Keywords: gadolinium retention; imaging agents; magnetic resonance imaging; positron emission tomography; yttrium
Mesh:
Substances:
Year: 2019 PMID: 31750991 PMCID: PMC7027945 DOI: 10.1002/anie.201911858
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336